Summary: The techniques involved in the transfer of foreign DNA to domestic animals have advanced to the stage where transgenic animals that express foreign genes can be reliably produced, albeit still at low efficiency. This paper reviews the current status of some of the more important areas in agriculture where this technology is being applied. Numerous attempts have been made to modify the growth performance characteristics of domestic animals by the introduction of metallothionein/growth hormone fusion genes. A summary of our work with transgenic sheep is presented. The results demonstrate that the unregulated production of growth hormone in transgenic sheep reduces carcass fat, elevates metabolic rate and heat production, causes skeletal abnormalities and impairs survival.
INTRODUCTION
The burgeoning size of the world human population is creating an unprecedented demand for agricultural products, while at the same time the environmental pressures of massive soil erosion and salination, industrial pollution, climatic change and urbanisation are reducing the amount of available farmland. The solutions available to this dilemma are limited. One possibility is to reduce the size of the human population, but this is unlikely to be achieved in the short term. Another is to create new land for farming, but there are cogent environmental reasons for maintaining the remaining forests of the earth in as natural a state as possible. A third possibility is to increase the efficiency of agricultural production. This is an attractive choice, but presents a challenge of some magnitude, because man has been directing much of his energy towards this goal for approximately ten millennia, with the result that the industry is already very efficient. Thus, significant new improvements will not be won easily.
The productivity of domestic animals has been improved by a combination of better husbandry practices and increased genetic potential. It is the latter of these that forms the subject of this review. Following the fundamental genetic principle that "like begets like", the genetic potential of a species can be steadily increased by the selective breeding of superior offspring. Progress is generally slow, but production increases of the order of 2-3% annually are possible. Most of this genetic improvement is the result of random re-assortment of existing genes to produce a more optimal combination, and it follows that without the input of new genetic material, eventually a selection plateau would be reached which would prevent significant additional productivity gains. Occasionally, however, a mutant form of an important gene is produced which has a major effect on production. Such an event is rare and unpredictable, but is a vital component in maintaining the general selection process. The new gene may behave as a single gene of major effect, or, alternatively, it may interact with other genes and exhibit a more complex pattern of inheritance. However, the introduction of new genetic material into the domestic species by this method of random mutation is subject to several major disadvantages. Because the mutations are random, it is very difficult to produce specific phenotypic effects. Many mutations are lethal, and this imposes a wasteful inefficiency on the process. In addition, the species barrier, which prevents breeding between different species, constitutes a major hurdle, because it effectively prevents a desirable gene in one species being used in another. It would, therefore, be of considerable advantage to animal selection programs if valuable new genes with known phenotypic response could be introduced into the genome of an animal without the requirement of conventional mating procedures. The recently developed techniques of genetic engineering show great promise as a way of achieving this goal. This new technology provides a mechanism for isolating single pieces of DNA, which can be manipulated in the test-tube, in order to alter the coding properties and regulation of the genes, the latter of which governs their expression in the animal.
The technique most frequently used consists of injecting a small amount of recombinant DNA into the pronucleus of a single-cell embryo, where it becomes integrated into the embryo genome. The newly incorporated DNA can contribute fully to the developmental program of the young embryo, and becomes an integral part of the genome of the animal that subsequently develops. The technique was pioneered in laboratory mice (2, 7, 30, 10, 11) and is widely used as a major research tool for the study of gene expression in this animal (3, 18) . The expression of the new gene in the adult is subject to numerous factors, such as the nature of the regulatory sequences included in the recombinant DNA gene construction, the position of integration of the DNA in the new genome and the compatibility of the transcription factors of the host. Nevertheless, there are now abundant examples of the expression of genes introduced by this "transgenic animal" technology and of the subsequent phenotypic modification of mice containing them.
There are a number of factors to be considered in order to adapt the mouse technology to the manipulation of domestic animals. Apart from establishing the mechanics of gene transfer in larger animals, which present their own unique set of problems, it is also important to decide which genes will be likely to influence an important production characteristic. Despite decades of research into the factors that influence production traits, in most cases detailed knowledge of physiology remains incomplete, and this presents a significant obstacle in selecting useful gene sequences. In those instances where a gene can be selected, it then becomes important to establish the correct control over the expression of the gene in its new host, and in the few examples that are available to date, this has proved to be difficult. In this review, the areas where the applications of the new technology are clearly identifiable will be discussed, together with the results that have been obtained to date, and some possible future applications.
ESTABLISHING THE TECHNOLOGY IN DOMESTIC ANIMALS
The technology that had proven to be successful in mice was quickly applied to domestic animals (12) . It was found possible in general to adapt the mouse procedures, albeit with somewhat lower efficiencies, but it was clear that some modifications of the procedure would be required for optimum performance in other species. As other laboratories began to repeat the techniques, it became apparent that each species presented its own set of unique problems (20, 15, 32, 13, 34, 24, 28) . These revolved around the ability of the operator to visualise the target pronuclei in the one-cell embryos, the efficient procurement of embryos, the injection of the embryos with the production of minimal cell trauma, and the optimal methodology for transferring the embryos back to recipient hosts. In the five years following the initial domestic animal successes, innovative solutions have been devised which today provide protocols for all the major domestic species, although the integration of the foreign DNA in domestic animals remains generally less efficient than in the mouse.
Our own laboratory has been concentrating mainly on the microinjection of sheep embryos. Sheep have proved to be one of the most difficult species to which the pronuclear microinjection technique could be adapted. The first transgenic sheep that was made contained a highly re-arranged piece of DNA, and the efficiency reported was 1.3%. Other laboratories also reported low efficiencies of integration (36, 28) , and it became clear that the sheep either did not integrate DNA at the same efficiency as other species, or that the species was particularly sensitive to damage during the microinjection procedure. The sheep pronuclei are frequently hidden by dense cytoplasmic granules, a problem which has also been encountered in other species, such as pigs and cattle. Whereas in pigs the granules can be effectively removed from the vicinity of the pronuclei by centrifugation, in sheep this is not very effective, and also reduces embryo viability. The most successful approach for sheep has been to carefully synchronise the developmental stage of the embryos by controlling the ovulation of the donors, since there appears to be a narrow window during the development of the embryo where the pronuclei are more easily observable. It is also important with sheep to ensure that the optics used to visualise the pronuclei are optimal (15, 13, 25, 28) . The success rates thus obtainable vary between 4% to 14%. This rate of success still leaves considerable room for improvement if it is to reach that of some other domestic animals such as pigs, for which the success rate varies between 10% (20) and 35% (31) . One possible route for improvement stems from a recent report that culturing post-injected sheep embryos in a synthetic culture medium containing human serum substantially increases the efficiency of production of transgenic animals (R. Seamark, unpublished data).
Despite the low efficiency with which transgenic domestic animals are created, the technology is adequate for experimental applications. The areas of physiology which are amenable to manipulation by genetic alteration are listed below: In altering the efficiency of a selected production trait by introducing new or modified genetic material to the target animal, two criteria apply. First, the physiology and biochemistry of the selected trait must be well understood. Second, a gene sequence must be available which can modify the trait. Because a substantial gap in knowledge exists between the observed or measurable physiology of an animal and the explanation of this physiology at the molecular level, there are few production characteristics within the broad categories listed above that can satisfy the above criteria. The areas that have received the most attention in the past few years are the manipulation of hormones, the introduction of new metabolic pathways to animals and the modification of mammary gland secretions.
ALTERING THE HORMONAL STATUS OF AN ANIMAL
The pioneering experiments of Palmiter et al. (16, 17) with laboratory mice, utilising a growth hormone coding sequence fused to a zinc-responsive metallothionein promoter sequence, demonstrated the remarkable phenotypic effect that could be produced in animals by the new gene transfer techniques. In these experiments, animals carrying the fusion gene grew faster and also grew to a larger size than control litter-mates. Application of these findings to domestic animals, however, has not proved easy. The promoter used by Palmiter and colleagues supported a substantial level of gene transcription in transgenic animals, even when their diet was not supplemented with the zinc inducer, resulting in animals that had chronically high levels of circulating growth hormone. The general health of these animals was good; however, the first suggestion that such high hormone levels might be deleterious was that the female transgenic mice were infertile. The effects of the same high hormone levels were much more pronounced when the metallothionein-growth hormone fusion genes were inserted into transgenic livestock. Pursel and colleagues inserted the genes into pigs (20) and obtained a small but significant growth response, but health problems became apparent within the first year of growth. Similarly, in sheep, the genes caused severe health problems (diabetes, bone abnormalities) without any observable growth increase above those of control animals (25, 15) .
In an attempt to attain regulatory control over the expression of the growth hormone gene, our laboratory has used the sheep metallothionein-la (sMT-Ia) promoter (19) , because experiments in cell culture had suggested that it may have a lower level of basal expression than those used in the Palmiter, Pursel and Rexroad experiments. The gene we constructed consisted of the sMT-Ia promoter fused to the coding sequence of the sheep growth hormone gene (15) . When this gene was inserted into transgenic mice, its expression was highly zinc-dependent (26) , in contrast with that of other MT/GH genes. The physiological consequences of this zincdependent expression in the mice were that enhanced growth occurred only when zinc was included in the diet, and that the females were fully fertile irrespective of whether or not the gene was induced. It therefore appeared to possess the properties that might make it useful in domestic animals, and, accordingly, the same gene was inserted into transgenic sheep. Somewhat to our surprise, the gene was expressed in sheep at a high level and the expression was independent of any dietary zinc supplementation. The concentration of growth hormone in the transgenic animals ranged from 402-42,500 ng/ml, in comparison with control values of 2.5-8 ng/ml. In one experiment, the zinc content of the diet was greatly reduced, but no significant change in growth hormone production was noted in the animals. The specificity of expression of the transgene in the transgenic sheep was measured in a variety of tissues in each of the animals immediately post-mortem. The major sites of expression were the liver, kidney and brain, although each animal had a different expression pattern. This contrasts significantly with the results obtained for this gene in zinc-induced transgenic mice, where the main sites of expression were the intestine and the kidney. It is clear from our experiments that it is not always possible to predict with confidence the manner in which a fusion gene will be expressed in one species on the basis of results obtained with another. The physiological consequences of the high levels of circulating growth hormone in the transgenic sheep in our experiments were similar to those reported by Rexroad et al. (25) . The fat content of the animals was greatly reduced, and basal metabolic rate and heat production were elevated. Insulin levels were elevated, and the animals all died before 12 months of age.
The main practical conclusion to be drawn from our results and those of other laboratories that have carried out similar experiments is that the continuous, unregulated release of growth hormone in transgenic animals is unlikely to prove useful for increasing the productivity of the species. There has been one encouraging report of a metallothionein-growth hormone gene inducing increased growth in a transgenic pig (31) . In this case, the fusion gene consists of the human metallothionein-II promoter joined to a porcine cDNA-genomic gene combination which encodes porcine growth hormone. One transgenic pig produced from this work exhibited an enhanced growth rate compared to controls, but no progeny were obtained from this animal. The level of gene expression in this animal was low, suggesting that this might be responsible for the enhanced growth without health defects. However, Pursel and colleagues have not found any correlation between low-level expression and lack of health problems, and so it will be important to wait until the Adelaide results are repeated by other laboratories. In any event, precise transcriptional control of the growth hormone transgene is clearly desirable if hormone production in the transgenic animal is to be limited to a short duration. Such gene control presents a challenge to molecular biologists and requires the evaluation of promoter sequences derived from genes other than those of the metallothionein family.
Some attempts have already been made to use other promoters and other coding sequences to control the production of growth hormone. Pursel and colleagues have introduced the gene encoding human growth hormone releasing factor into transgenic pigs and transgenic sheep (20) . This gene was placed under the control of the metallothionein promoter system or the mouse albumin gene promoter. With either promoter, the concentration of circulating growth hormone releasing factor was elevated between 10-fold and 500-fold, but growth hormone concentrations were not altered. Another series of experiments has recently been reported in which the promoter from the gene encoding phosphoenolpyruvate carboxykinase (PEPCK) was joined to the bovine growth hormone gene (33, 14) . This promoter is controlled by the ratio of carbohydrate to protein in the diet of the animal, and in transgenic mice was able to regulate the level of growth hormone production. The results with transgenic pigs remain to be fully evaluated, but preliminary results suggest that, in these animals, growth hormone production is still not sufficiently controlled to prevent the development of health defects and physiological problems (33) . To date, no clear example exists of a promoter that could be used to regulate animal growth and productivity in a way that would be of practical value to the farming community. Failure to identify such a promoter emphasises the complexity of the problem.
THE INTRODUCTION OF NEW METABOLIC PATHWAYS TO ANIMALS
The most exciting potential of the new gene transfer techniques is its ability to overcome the barrier which prevents the transfer of genetic information between different species. In theory, the entire genetic repertoire of the plant and animal kingdoms is now available as a resource for the improvement of animal productivity. One application of this is the removal of substrate limitations to productivity which result from the loss of important biochemical pathways. Wool growth is one production trait that is amenable to influence by this approach. The physiology of wool production has been the subject of considerable research. As a result, the nutritional requirements for the process are at least partially understood. The work of Reis and co-workers (23, 21, 22, 4) has shown that one of the limiting factors is the supply of the essential amino acid cysteine to the wool follicle. In addition, much of the energy supply to the wool follicle is provided by glucose (5, 9), a substrate which is less readily available in ruminants than in monogastric animals. In order to overcome these limitations, we are attempting to introduce two metabolic pathways into sheep, which together are predicted to increase the availability of cysteine and glucose to the wool follicle. The two pathways involved are the cysteine biosynthetic pathway and the glyoxylate cycle. Their relevance to wool follicle activity is shown diagrammatically in Figure 1 . Each pathway requires the presence of two new enzymes, the coding sequences for which have been lost to the mammalian genomes during evolution. As it is now possible to cross broad genetic boundaries, our approach is to utilise the functional coding sequences which are present in the genome of Escherichia coli.
The high cysteine content of the wool keratin proteins (9) is consistent with findings that its supply plays an important role in fibre growth. Thus it follows that wool growth can be improved if a way can be found to increase the amount of cysteine that is absorbed from the diet of sheep. However, the ruminant digestion of the species makes this difficult, because if an excess of cysteine is simply added to the diet of the animal, it is degraded by the rumen bacteria. A number of different approaches have been taken over the years, aimed at increasing the amount of circulating cysteine in sheep by preventing degradation in the rumen, but none has proven to be cost-effective in a grazing situation. The relevant portion of the cysteine biosynthetic pathway in E. coli that is required for our work is shown in Figure 1 . The pathway is catalyzed by two enzymes, serine transacetylase (SAT) (EC.2.3.1.30) and O-acetylserine sulfhydrylase (OAS) (EC.4.2.99.8). Sheep do not possess the genetic information for either of these enzymes, and, therefore, can only synthesise cysteine from other sulphur-containing amino acids such as methionine, itself an essential amino acid. Our aim is to isolate the appropriate genetic information from the bacterium E. coli, place it under eukaryotic promoter control such that it will be transcribed in the ruminai and intestinal epithelia of the sheep, and transfer it to sheep by pronuclear microinjection. We predict that the presence of SAT and OAS in these tissues will result in the biosynthesis of cysteine, for which endogenous serine, which is present as a non-essential amino acid, and H 2 S, which is produced in the rumen and intestine, will serve as substrates (35) .
In order to increase the availability of glucose to the follicle, we intend to introduce the glyoxylate cycle, a pathway which can shunt the tricarboxylic acid cycle in such a way that acetate can be used as a substrate for gluconeogenesis. Sheep, like all ruminants, have no dietary supply of glucose because it is metabolised by microbes in the rumen. Glucose is subsequently synthesised from gluconeogenic precursors, such as volatile fatty acids and amino acids. Acetate, however, is a major component of these volatile fatty acids, but does not give rise to glucose because it must enter the tricarboxylic acid cycle where two decarboxylation steps ensure that no net carbon utilisation can take place. While acetate can therefore be a major source of energy supply for those tissues which have a highly aerobic metabolism, it is largely lost to the glucose-demanding wool follicle. The glyoxylate cycle provides a metabolic shunt which prevents the loss of acetate carbon in the decarboxylation steps of the tricarboxylic acid cycle. In E. coli, this shunt consists of two genes, aceA, encoding the enzyme isocitrate lyase (EC.4.1.3.1), and aceB, encoding malate synthase (EC.4.1.3.2). The operation of these genes to produce succinate and malate is shown in Figure 1 . The experimental approach used to introduce these genes to sheep is essentially the same as that used for the cysteine biosynthetic pathway. We intend to place the E. coli genes under the control of an sMT-Ia promoter in order to obtain expression in tissues, thus increasing the supply of glucose for general circulation. In addition, we intend to place the genes under the control of a promoter which will direct expression specifically in the wool follicle, in order to increase the amount of glucose in the follicle itself.
The modification of the various bacterial genes has been similar in principle for each gene. The promoter was the sMT-la sequence that was used in our growth hormone fusion gene. This sequence possesses many of the features which are desirable in the regulation of the new metabolic pathways. The bacterial coding sequences were cloned from E. coli and identified by sequencing. The sMT-la promoter was fused to the 5' portion of each gene immediately upstream from the bacterial ATG initiation codon. In order to provide a stable messenger RNA, the sheep growth hormone gene was fused to the 3' end of the bacterial coding sequence. The ATG initiation codon of the growth hormone gene was removed prior to this fusion, thus reducing the likelihood of a growth hormone gene product being translated from the mRNA transcribed from the fusion genes. The structures of the various genes are shown in Figure 2 .
After the bacterial sequences were modified, it was necessary to determine whether they would be expressed in eukaryotic cells. This was examined by inserting four Plasmids, pMTCEll, pMTCKll, pMTaceAl and pMTaceBl, into mouse L-cells and measuring transcription by Northern blot analysis both in transient and stably transformed cells. As shown in Figures 3 and 4 , all four plasmids gave transcripts of the sizes predicted from the structure of the genes. Furthermore, an increase in the intensity of the transcripts in cells grown in the presence of zinc indicated that the heavy metal-inducibility of the MT-la promoter had been retained. To further demonstrate that the genes were functional in cell culture, the enzyme levels were also measured in cell extracts obtained from the transformed cell lines. Table I shows the levels of the cysteine biosynthetic enzymes SAT and OAS. Thus, SAT activity of 225 nmoles O-acetylserine formed/mg protein/30 min was measured in cells transformed with the pMTCEll plasmid, and OAS activity of 1,500 nmoles cysteine formed/mg protein/30 min was measured in cells transformed with the plasmid pMTCKl1. The activity of both enzymes was increased in the cell cultures when they were grown in the presence of zinc, which further indicates that the fusion genes can be induced by zinc. Table II shows genes. Cysteine biosynthesis from serine and H 2 S was demonstrated by incubating radioactively-labelled serine with cell extracts and observing the appearance of radioactive cysteine. The amount of radioactive cysteine produced was detected, but it was much less than that predicted from the levels of the two individual enzymes. In the cell line containing the glyoxylate cycle, we have not been able to demonstrate the production of malate from isocitrate in cell extracts, which suggests that at least one of the enzymes may be present at too low a level for significant operation of the pathway.
The next stage in the evaluation of the genes was to determine their capacity for expression in transgenic animals. Thus, the inserts from plasmids pMTCEll, pMTCKll, pMTaceAl and pMTaceBl were introduced into transgenic mice by pronuclear microinjection. Southern blot analysis of the various transgenic animals showed that the various genes were inserted in the usual tandem arrays that are associated with such animals, and that most of the genes were arranged in a normal head-to-tail configuration. Expression of the various fusion genes in the transgenic progeny was examined both by Northern blot analysis of RNA extracted from a variety of tissues, and by enzyme analysis of tissue extracts. As shown in Figure 5 , the only gene to give rise to detectable levels of expression in animals was MTaceAl. In the transgenic mouse line established with this gene, a low-level transcript was present in RNA extracted from liver, but was absent in testis and brain. The other acecontaining gene, MTaceB1, and the two cys-encoding genes, MTCE11 and MTCK11, did not give rise to RNA transcripts in any of the animals examined.
One of the cys-encoding genes was also inserted into a transgenic sheep, in order to determine whether the poor expression of these genes in mice was also found in sheep. The gene used was pMTCK12, a slight variant of pMTCKl1 in which 41 base pairs of the GH first exon were interposed between the sMT-la promoter and the bacterial cysK coding sequence. This gene construction was used because cell culture data indicated it might be slightly better expressed in mouse L-cells. Southern blot analysis of the DNA from the transgenic sheep indicated that the gene was integrated without obvious re-arrangement, and biopsy samples of skin and liver were examined for expression of the gene. However, no detectable expression was observed in Northern blots of RNA extracted from these tissues, and it appears likely that the same poor expression observed in mice will also be manifest in this sheep.
Since the genes are not re-arranged in these animals, we conclude that when a bacterial gene is inserted between the sMT-la promoter and the sheep growth hormone gene, the high levels of zinc-inducible expression observed with the unaltered MTsGH9 gene in transgenic animals are not obtained. Accordingly, we have recently constructed a series of genes containing different portions of the sheep growth hormone sequence fused to the 3' end of the bacterial coding sequence, and compared the expression of these constructions in mouse L-cells. Several of these have levels of expression an order of magnitude greater than that of the original gene constructs, and these are currently being inserted into transgenic mice and sheep for in vivo evaluation. Our results serve to demonstrate the difficulties that might reasonably be expected to occur during the transfer of genes between organisms that have diverged widely during evolution. However, our current progress is highly encouraging, since it shows that it is possible to obtain expression of bacterial metabolic pathways in eukaryotic cells. The limited expression that has already been achieved supports our view that the pathways will also be functional in animals, once the optimal gene arrangement is found. This is further supported by the recent reports that the cysE gene of Salmonella typhimurium has been expressed in the skin of transgenic mice (29) and transgenic sheep (G.E. Rogers, unpublished findings). In these experiments, a murine leukaemia virus promoter was used to initiate transcription of the gene. This particular promoter is unlikely to provide the necessary tissue-specific expression required for the practical operation of the metabolic pathway in sheep, nevertheless, results obtained with it provide convincing evidence that using gene transfer to modify the biochemistry of domestic animals is a viable approach.
THE MANIPULATION OF MILK PROTEIN COMPOSITION
The manipulation of milk protein genes is another area that is attractive as a way of improving domestic animal productivity. There are two different approaches to this problem. The first is to alter the amount or the amino acid composition of the existing milk proteins, in order to improve milk quality. However, there has been no reported research on this aspect as yet. The other approach is to manipulate the milk composition by introducing genes, placed under the control of a mammary glandspecific promoter, into transgenic animals that encode valuable pharmaceuticals. The successful production of human factor IX protein and (alpha 1) antitrypsin has already been achieved in transgenic sheep with this approach (37, 28, 6, 27) . Mammary glandspecific expression was obtained by fusing cDNAs encoding the human hormones with the ovine beta-lactoglobulin gene. As was found with the research on bacterial pathways discussed above, the levels of expression of the initial gene constructs were too low to be of commercial value, but it was extremely encouraging to note that the expression of the hormones was tissue-specific.
This approach to the use of transgenic animals is innovative and has a high probability of ultimate success, both as a scientific research program and as a commercial enterprise. As might be expected, there are a number of problems yet to be solved before it becomes a practical proposition. These include the establishment of methods to purify the desired hormone from the milk, and the need to ensure that glycosylation of the hormones is sufficiently similar to that of the native hormone to prevent it being antigenic, since otherwise an antibody reponse might be provoked. However, in the long term this approach offers a way of providing essentially unlimited quantities of valuable peptide hormones for human pharmaceutical use.
CONCLUSIONS
It is now almost five years since the first transgenic domestic animals were reported, and it has become apparent that the major hurdle yet to be overcome before the technology fulfils its promise is the transcriptional control of the inserted genes. The difficulty that is faced in this research is the long generation time of the domestic species, which substantially delays the time from insertion of a transgene into an animal to evaluation of the performance of the gene. Our own results have shown that, although expression of transgenes in mice is a useful guide to performance in domestic animals, nevertheless, major differences can be experienced when the gene is placed in the larger animals. However, it has now been demonstrated that transgenes can be expressed in domestic animals, as well as in laboratory mice, and that this expression can dramatically affect the phenotype of the animal. Furthermore, progress has been made towards the construction and transfer of genes with the potential to modify domestic animal biochemistry, although research must yet be completed in order to attain the desired level of tissue-specific expression of these fusion genes in transgenic livestock. It is obvious that short-term application of the technology is not realistic. Once adequate control of the various fusion genes is achieved, it will be necessary to carry out extensive breeding and physiological testing in order to confirm the practical usefulness and general safety of the transgenic animals. The technology has the potential to help overcome many of the pressing agricultural problems facing our society, but, if this is to happen, transgenic animals must be evaluated with great care, and such research cannot be hurried.
The paucity of detailed knowledge of the physiology of domestic animals is currently inhibiting the application of gene transfer to productivity improvement. Since the technology has, as an absolute requirement, the isolation of one or more genes which are able to influence a selected physiological process, it is necessary to be able to understand such physiology at the molecular level. It is only in a few instances that this requirement can be fulfilled at present, and thus it is mandatory that further detailed research be conducted into the important areas of reproductive physiology, digestion, temperature control, behaviour and even intermediary metabolism, which is still incompletely understood in ruminants. The knowledge that will accrue from this work will inevitably lead to the identification of compounds that are important to the various physiological processes, and these in turn will lead to the identification of useful genes. In addition to this work, the finely detailed gene mapping of our domestic species is of considerable importance to the future of gene transfer. This may lead to the identification and isolation of genes that are associated with production traits, even if the precise mechanism of involvement is not initially understood. Such a task is formidable, but recent progress in restriction fragment length polymorphism analysis and chromosome walking technology has made the approach feasible.
The future looks very promising for transgenic domestic animals to benefit agricultural production. Patience will be required on the part of the industry, because technology is continually breaking new ground, and responsibility will be required on the part of the scientists in order to ensure that the eventual genotypes that are released will be of long-term benefit both to the farmer and to the ecosystem of the earth.
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La introducción de nuevas vías metabólicas en los animales domésticos ofrece un enfoque atractivo para mejorar la productividad animal. El presente artículo resume los recientes resultados de la investigación destinada a introducir en carneros transgénicos una vía de biosíntesis de la cisterna, así como el ciclo de glioxilato. Hasta la fecha, se han aislado genes que codifican las enzimas y se han expresado en células de cultivo y en ratones transgénicos. Los resultados muestran que se requiere una modificación de los genes de fusión para mejorar su expresión en los animales transgénicos, trabajo que se encuentra actualmente en realización.
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